GenEdit is a next-generation genome editing company developing non-viral delivery technologies for the CRISPR/Cas9 gene editing system that can safely and efficiently correct gene mutations in patients. CRISPR/Cas9 is a powerful genome editing tool that makes therapeutic gene editing possible. Easier to use, faster, and more accurate than previous gene editing techniques and having the potential for a wide range of therapeutic applications, CRISPR/Cas9 gene editing has the potential to treat a variety of incurable genetic diseases. Current CRISPR delivery methods, however, rely on viruses and are problematic due to viral-induced toxicity and prolonged Cas9 exposure, increasing off-target effects. The need is for a non-viral CRISPR/Cas9 delivery method. In addition, low efficiency levels achieved with current CRISPR make it impossible to target certain diseases. GenEditÂ’s novel CRISPR delivery technology has the potential to be a platform delivery system for a broad range of genetic diseases. Principals of the firm are also working on engineering of core components of CRISPR/Cas9 genome editing system to increase editing efficiency and enable targeted delivery.
